Noonan Syndrome Market worth USD 2.11 Bn by 2032, growing at 9.7% CAGR, says Coherent Market Insights

May 15, 2025 |

1 min read

The Global Noonan Syndrome Market size was valued at US$ 1.10 Billion in 2025 and is expected to reach US$ 2.11 Billion by 2032, growing at a compound annual growth rate (CAGR) of 9.7% from 2025 to 2032, as highlighted in a new report published by Coherent Market Insights. The Noonan syndrome market is witnessing notable growth, driven by progress in genetic testing and the rise of personalized medicine. Cutting-edge technologies like next-generation sequencing and CRISPR are improving both diagnostic accuracy and treatment possibilities.

Get a Sample of the Report (Use Corporate Email ID for a Quick Response): https://www.coherentmarketinsights.com/insight/request-sample/7718

Global Noonan Syndrome Market Key Takeaways

Recording a CAGR of 9.7%, the global Noonan syndrome market size is expected to grow from USD 1.10 Bn in 2025 to USD 2.11 Bn by 2032, owing to increasing number of diagnosed cases globally and growing demand for targeted therapies.

Based on test, the ultrasound test segment is expected to account for nearly one-third of the global Noonan syndrome market share in 2025.

By treatment, growth hormone therapy segment is set to dominate the target industry, holding a market share of nearly 1/4 in 2025.

Regarding route of administration, oral segment will likely account for a revenue of about USD 0.49 Bn in 2025.

As per Coherent Market Insights’ latest Noonan syndrome market analysis, North America is expected to retain its dominance, accounting for a revenue share of 36.3% in 2025.

Asia Pacific, led by China and India, is projected to be the fastest-growing market for Noonan syndrome treatments during the forecast period. As per CMI’s latest global Noonan Syndrome market research, the region will likely account for more than one-fourth of the global industry share in 2025.

Advances in Genetic Testing and Diagnostics Boosting Market Growth

The Noonan syndrome market is set to experience robust growth during the assessment period. This is mainly due to improved diagnostic rates and ongoing advances in genetic testing and diagnostics.

Noonan syndrome is a genetic disorder that affects various parts of the body. It is estimated to affect 1 in 1,000 to 1 in 2,500 births. Advances in genetic testing are making early and accurate diagnosis of this syndrome more common. This is expected to drive demand for Noonan syndrome tests and treatments.

Advanced diagnostic technologies such as next-generation sequencing (NSG) are revolutionizing the way genetic disorders like Noonan syndrome are identified. They empower clinicians to rapidly and quickly pinpoint mutations in genes. Rising adoption of these technologies, along with an increasing number of diagnosed Noonan syndrome cases, will play a key role in boosting market growth.

Also Read: Impact of Rising Genetic Disorder Prevalence on Genetic Testing Market Size and Share (2025-2032)

Regulatory and Technical Challenges Restraining Market Growth

The future Noonan syndrome market outlook looks promising. However, some factors are limiting market growth to some extent. These include limited treatment options and high cost of Noonan syndrome treatments and tests.

Low availability of approved treatments for Noonan syndrome results in an unmet medical demand. Currently, there is no permanent cure for Noonan syndrome. Treatments only focus on managing symptoms and complications associated with the condition to improve quality of life.

Genetic testing, growth hormone therapy, and other supportive treatments are expensive. This deters people from seeking diagnosis and care, which may limit overall Noonan syndrome market demand.

Emergence of Targeted Therapies Creating New Growth Prospects

Rise in diagnosis rates of Noonan syndrome is creating immense demand for effective treatments. To capitalize on these emerging opportunities, companies are striving to develop targeted therapies aimed at alleviating the symptoms and health complications associated with Noonan syndrome.

Development of targeted therapies is offering new hope for those affected by Noonan syndrome. Rising approval and adoption of these targeted therapies for managing symptoms and complications is expected to boost growth of the Noonan syndrome market during the forecast period.

Get Customization on this Report: https://www.coherentmarketinsights.com/insight/request-customization/7718

Emerging Noonan Syndrome Market Trends

There is growing interest in personalized medicine to manage the symptoms and complications of Noonan Syndrome. In response, researchers and biotechnology companies are exploring targeted treatment approaches based on individual genetic mutations associated with the condition.

Growth hormone therapy is gaining immense traction among individuals with short stature associated with Noonan syndrome. High adoption of this growth hormone therapy is expected to boost Noonan syndrome market growth throughout the forecast period.

Many governments and private companies are increasingly providing financial support for advancing research into the underlying mechanism of Noonan syndrome. This will likely facilitate the development of innovative treatments as well as improvements in existing ones.

Research institutions, biotech firms, and pharmaceutical companies are collaborating to explore new Noonan syndrome treatments with high efficacy. Growing popularity of these strategies will contribute to expansion of the Noonan syndrome market.

Also Read: Next Generation Sequencing Market: Growth, Size, Share, and Trend for 2025 to 2032

Analyst’s View

“The global Noonan syndrome market is poised for rapid growth, driven primarily by rising diagnosis rates, increasing government initiatives, and development of target therapies,” said senior analyst Ghanshyam Shrivastava.

Current Events and Their Impact on the Noonan Syndrome Market

Event	Description and Impact
Increasing Awareness	Description: Rising public awareness of Noonan syndrome is leading to higher diagnosis rates. Impact: Increasing diagnosed cases will drive demand for Noonan Syndrome treatments.
Advancements in Genetic Research	Description: Ongoing advances in genetic research are paving way for the identification of new genetic markers for Noonan syndrome as well as development of targeted gene therapies. Impact: Improved diagnostic accuracy and potential curative treatments are expected to boost growth of the Noonan syndrome market.
Technological Advancements	Description: Ongoing improvements in genetic sequencing and molecular diagnostics techniques are leading to more efficient and cost-effective diagnosis of Noonan syndrome. Impact: These advancements will play a key role in improving the overall Noonan syndrome market value.

Competitor Insights

Key companies listed in Noonan Syndrome market report:

- Invitae Corporation

- Laboratory Corporation of America

- CENTOGENE N.V.

- Sema4

- NeoGenomics Laboratories

- Paragon Genomics, Inc.

- Pfizer Inc.

- PerkinElmer Inc.

- Illumina, Inc.

- Merck KGaA

- Eurofins Scientific

- USV Private Limited

- Bio-Rad Laboratories, Inc.

- Novo Nordisk A/S

- Genentech, Inc.

Key Developments

In May 2024, BioMarin Pharmaceutical Inc. announced positive results from an investigator-sponsored Phase 2 study of VOXZOGO in children with various genetic growth-related conditions, including idiopathic short stature and Noonan syndrome.

In March 2024, Invitae launched an update to its Invitae Generation with Clinical Variant Modeling to aid clinical interpretation of genetic testing results as well as increase the rate of definite answers for patients.

Also Read: Gene Therapy for Rare Disease Market Size and Share Analysis (2025-2032)

Get Recent News:
https://www.coherentmarketinsights.com/news

Read Recent Blogs:
https://www.coherentmarketinsights.com/blog

About Us:
Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

For Latest Update Follow Us:
LinkedIn | Facebook | Twitter